表紙:バイオ医薬品チューブの世界市場-2023-2030
市場調査レポート
商品コード
1272768

バイオ医薬品チューブの世界市場-2023-2030

Global Biopharmaceutical Tubing Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.33円
バイオ医薬品チューブの世界市場-2023-2030
出版日: 2023年05月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

バイオ医薬品チューブの世界市場は、2022年に35億8,040万米ドルに達し、2030年には66億7,420万米ドルに達することで有利な成長が予測されます。バイオ医薬品チューブ市場は、予測期間中(2023年~2030年)に8.3%のCAGRを示すと予想されます。白金硬化シリコーンチューブの発売と素材としての使用は、予測期間中、バイオ医薬品チューニング市場の重要な動向として浮上すると思われます。

したがって、プレーヤーは、優れたコスト効率の良い製品でバイオ医薬品チュービング市場に参入する大きな機会を得ることができます。例えば、2020年1月、Watson-Marlow Fluid Technology Group(WMFTG)は、幅広いバイオプロセス流体移送アプリケーションのための安全で信頼性が高く、コスト効率の良いソリューションを与えるBioPureシリコーン移送チューブを発売しました。

バイオピュアシリコンチューブは、半透明で破れにくいチューブです。医薬品やバイオテクノロジー製品の製造工程で使用されるように設計されています。医薬品やバイオテクノロジーの用途で使用されるチューブには、一定の仕様があります。抽出可能な化合物を使用する場合、滅菌処理に耐える能力、検査結果が陽性であることの伝達能力などです。

滅菌が容易で、純度が高く、柔軟性があり、副作用がないなど、他の材料に比べて多くの利点があるため、シリコーン製バイオ医薬品チューブの採用が増加するなど、いくつかの要因によって、バイオ医薬品チューブ市場の成長率は高いです。バイオ医薬品チューブの市場規模には、シリコーン、金属、プラスチックなどのバイオ医薬品チューブの種類や、製薬・バイオ医薬品、臨床、研究開発など様々な分野での用途が含まれます。

市場力学

高齢者人口の増加と戦略的イニシアティブが、バイオ医薬品チューブ市場の成長を促進する

バイオ医薬品チューブの世界市場は、高齢者人口の増加に伴い拡大しています。平均寿命の延びは、世界における高齢者人口の増加をもたらしています。世界保健機関(WHO)によると、60歳以上の世界人口シェアは、2015年の12%から2050年には22%へとほぼ倍増するとされています。

国連の世界人口高齢化報告書によると、2017年、世界の60歳以上の人口は9億6,200万人で、2050年には~21億人に達すると予想されています。

さらに、製品の発売、買収、合併、パートナーシップなどの戦略的イニシアティブも、市場に有利な成長をもたらすでしょう。例えば、2021年4月、BioCardia Helixカテーテル生物治療薬送達製品の可能性に関する、再生医療開発企業であるBioCardia, Inc.は、日本のトップバイオテクノロジー企業の1つと契約を締結しました。これは、BioCardia Helixカテーテルを用いたバイオセラピューティクスを特定の細胞種で心臓に投与するための非独占的かつ世界なライセンスです。

メーカーにとって、拡大する研究開発と技術的なブレークスルーは、非常に大きな拡大機会をもたらします。バイオ医薬品チューブは、製薬・バイオ医薬品業界が物質や材料の輸送に使用することが増えているため、バイオ医薬品チューブの市場機会は非常に大きいです。

研究開発と技術の進歩が進み、メーカーにとって有利な成長の見込みがあります

バイオ医薬品チューブは、製薬会社やバイオ医薬品会社で化合物や材料の輸送に広く受け入れられつつあるため、かなりの市場機会があります。シリコーン製や金属製のバイオ医薬品チューブのような製品の需要が求められるため、メーカーは成長のための有益な選択肢を得ることができるでしょう。

シリコーンチューブやホースは、バイオ医薬品のCIP(clean-in-place)やSIP(sterilize-in-place)操作で使用される典型的な化学物質の搬送に使用することができます。医薬品やバイオ医薬品の用途で使用されるチューブには、一定の仕様があります。現在、さまざまな種類のシリコーンチューブが研究開発されていますが、その前に、無毒性や清浄性など、医療分野での使用基準を満たすことが必要です。

医療用シリコーンチューブは、無臭、無毒、無味の化合物組成であること。また、細菌の繁殖を助長するような傾向があってはなりません。したがって、技術の進歩や研究開発の高まりが市場の成長に寄与しています。

バイオ医薬品チューブの使用に伴うデメリットや制限事項

動物成分や動物由来の化合物を含む製品を加工する場合、製薬会社やバイオ医薬品会社の大半は、動物成分や完成品への影響に関連した問題に遭遇しています。チューブの素材は、時として工業用化合物と反応することがあります。

また、シリコーンオイルも危険な素材である可能性があります。シリコーンオイルが他の成分と反応し、製品に残留することがあります。医薬品・バイオテクノロジー分野では、溶接不良やチューブ内面が腐食・汚染の主な原因となっています。

チューブや継手は製品流体と接触する表面積の90%を占めることから、これらの部品はトラブルのない製造のために、高品質の溶接を簡単かつ一貫して行えるように製造する必要があります。

このレポートの詳細について- サンプル請求

COVID-19の影響分析

COVID-19の分析では、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオに加え、価格力学(パンデミック時の価格変動、COVID前のシナリオとの比較など)、需要-供給スペクトラム(取引制限、封鎖、事後問題による需要と供給のシフト)、政府の取り組み(政府機関による市場、産業、分野の活性化の取り組み)、メーカーの戦略的取り組みが含まれています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、この地域の主要な市場プレイヤーの数が少ないため、世界のバイオ医薬品チューブ市場に与える影響は少ないと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のバイオ医薬品チューブ市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • タイプ別スニペット
  • スニペット:用途別
  • スニペット:地域別

第4章 市場力学

  • 影響要因
    • 促進要因
      • 高齢者人口の増加と戦略的な取り組み
      • シングルユースシステム(SUS)の用途拡大
    • 抑制要因
      • バイオ医薬品チューブの使用に伴う欠点または制限
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 法規制分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19導入前シナリオ
    • 現在のCOVID-19シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • サマリー

第7章 タイプ別

  • シリコーン
  • プラスチック
  • 金属

第8章 用途別

  • 医薬品・バイオ医薬品
  • 臨床分野
  • 研究開発用
  • 診断分野

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A(合併・買収)分析

第11章 企業プロファイル

  • W. L. Gore and Associates, Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展状況
  • DuPont de Nemours, Inc.
  • Freudenberg Group(Freudenberg Medical)
  • REHAU Group(Raumedic AG)
  • Genstar Capital LLC(TekniPlex)
  • Holland Applied Technologies, Inc.
  • Sartorius AG
  • Saint-Gobain
  • Ami Polymer
  • Nordson Corporation

第12章 付録

目次
Product Code: MD4254

Market Overview

The global biopharmaceutical tubing market reached US$ 3,580.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,674.2 million by 2030. The biopharmaceutical tubing market is expected to exhibit a CAGR of 8.3% during the forecast period (2023-2030). The launch and use of platinum-cured silicone tubing as a material of choice will likely emerge as a significant trend in the biopharmaceutical tuning market during the forecast period.

Thus, the players have significant opportunities to enter the biopharmaceutical tubing market with superior and cost-effective products. For instance, in January 2020, Watson-Marlow Fluid Technology Group (WMFTG) launched BioPure silicone transfer tubing to confer safe, reliable, and cost-effective solutions for a wide range of bioprocess fluid transfer applications.

Biopharmaceutical tubing is tear-resistant that is translucent. It is designed for use in manufacturing procedures for pharmaceutical and biotechnology products. Tubing utilized in pharmaceutical or biotech applications has certain specifications. When using extractable compounds, the capacity to endure sterilizing procedures and the transmission of positive test results.

The biopharmaceutical tubing market growth rate is high, owing to several factors including the rising adoption of silicone biopharmaceutical tubing due to the number of advantages these have over other materials, such as its ease of sterilization, inherent purity, pliability, and no side effects. The biopharmaceutical tubing market scope includes the type of biopharmaceutical tubing which include silicone, metal, or plastic or the applications of these tubing in various fields such as pharmaceutical and biopharmaceutical, clinical or research and development.

Market Dynamics

The increasing elderly population and strategic initiatives drive the growth of the biopharmaceutical tubing market

The global market for biopharmaceutical tubing is expanding as a result of the rising elderly population. The increase in life expectancy is leading to a rise in the geriatric population in the world. According to the World Health Organization (WHO), the global population share of people with age more than 60 would nearly double from 12% in 2015 to 22% in 2050.

According to the United Nations World Population Ageing Report, in 2017, there were 962 million people with age 60 or above in the world, and the number is expected to reach ~2.1 billion by 2050.

Additionally, strategic initiatives such as product launches, acquisitions, mergers, partnerships, or others will also provide lucrative growth to the market. For instance, in April 2021, concerning the potential of BioCardia Helix catheter biotherapeutics delivery products, BioCardia, Inc., a regenerative medicine developer company, entered into a contract with one of the top Japanese biotechnology firms. It is a non-exclusive, global license for the delivery of biotherapeutics using the BioCardia Helix catheter in particular cell types for cardiac reasons.

For manufacturers, the expanding R&D and technical breakthroughs open very significant expansion opportunities. Biopharmaceutical tubing has a huge biopharmaceutical tubing market opportunity since pharmaceutical and biopharmaceutical industries are increasingly using it to transport their substances or materials.

The growing research and development and technological advancements create lucrative growth prospects for manufacturers

There is a sizable market opportunity for biopharmaceutical tubing, as it is becoming more widely accepted in pharmaceutical and biopharmaceutical companies for the transportation of their compounds or materials. Manufacturers are going to have profitable choices for growth as demand for products like silicone or metal biopharmaceutical tubing will be required.

Silicone tubing and hoses can be used to convey the typical chemicals used in biopharmaceutical CIP (clean-in-place) or SIP (sterilize-in-place) operations. Tubing employed in pharmaceutical as well as biotech applications has certain specifications. The various varieties of silicone tubing are now being researched and developed, but before that can happen, the product must first satisfy the standards for usage in the medical industry, including non-toxicity and cleanliness.

Medical-grade silicone tubing attributes compound compositions that make it odorless, non-toxic, and tasteless. It must not have any tendency that supports bacterial growth. Hence, rising technological advancements or research and development are contributing to the growth of the market.

The disadvantages or limitations associated with the use of biopharmaceutical tubing

When processing products that contain any animal ingredients or compounds derived from animals, the majority of pharmaceutical and biopharmaceutical firms have encountered issues linked to animal ingredients and their possible effects on completed products. Tubing materials can occasionally react with industrial compounds.

Another potentially dangerous material is silicone oils. A residue may be left in the completed product as a result of the oils reacting with other ingredients. Poor welding and inner tube surfaces are the main causes of corrosion/contamination issues in pharmaceutical and biotech operations.

Given that the tubes and fittings make up 90% of the surface area in contact with the product fluid, these parts must be manufactured to make high-quality welding simple and consistent to ensure trouble-free manufacturing.

For more details on this report - Request for Sample

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterwards issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global biopharmaceutical tubing market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global biopharmaceutical tubing market growth over the forecast period.

Segment Analysis

The global biopharmaceutical tubing market is segmented based on type, application and region.

Pharmaceutical and biopharmaceutical segment account for 50.8% of the biopharmaceutical tubing market share, owing to rising demand for tubing in biopharmaceuticals.

The pharmaceutical and biopharmaceutical industry is currently growing due to huge demands owing to the increasing population. Various product launches and formulations are taking place to meet the demand for several products utilizing biopharmaceutical tubing due to its various advantages and characteristics crucial for manufacturing.

Specialized tubing with high quality is crucial for designing an efficient pharmaceutical and biopharmaceutical system for fluid processing. One must take special considerations to avoid possible product contamination found within specific tube composites as residues.

Pharmaceutical and biopharmaceutical manufacturing usually involves batch sample retention and producing drug or substance specimens. These samples (liquid) are continuously stored in small bags with tubing attached. This tubing should be sealed permanently without breaking sterility, using heat and compression to prevent contamination and spillage.

Various key players are developing and launching novel products with the latest innovations. For instance, on May 18, 2022, Freudenberg Medical, a biopharmaceutical and clinical tubing and components manufacturer, introduced its high-purity thermoplastic elastomer tubing HelixFlex, developed for different biopharmaceutical and pharmaceutical applications.

Geographical Analysis

North America holds 40.1% of the market share owing to the strong presence of major players and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for biopharmaceutical tubing for several operations in bioprocessing and storage in North America. The area has many producers and suppliers, and its rapid economic development has increased the industrial production of biopharmaceutical tubing, which has increased the demand.

Growth is also fueled by rising technological advancements and novel product launches. For instance, the AdvantaPURE product portfolio of biopharmaceutical tubing includes various options in its series AdvantaFlex or AdvantaSil. It includes biopharmaceutical pump tubing, platinum-cured silicone tubing and reinforced tubing, and reinforced FEP, PTFE, and EPDM tubing.

AdvantaPURE develops tubing for different needs, such as high-pressure silicone tubing, low-temperature silicone tubing, and tubing specifically developed for the durability of pumping systems and tubing which enhance the pressure capabilities. The aforementioned elements show North America's supremacy on a worldwide scale.

Competitive Landscape

The major global players in the biopharmaceutical tubing market include W. L. Gore and Associates, Inc., Rehu Group (RAUMEDIC AG), Freudenberg Group (Freudenberg Medical), Genstar Capital (Tekni-Plex, Inc.), Holland Applied Technologies, Inc., DuPont de Nemours, Inc., Sartorius AG, Ami Polymer, Saint-Gobain and Nordson Corporation among others.

Why Purchase the Report?

  • To visualize the global biopharmaceutical tubing- market segmentation based on type, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of biopharmaceutical tubing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global biopharmaceutical tubing market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Elderly Population and Strategic Initiatives
      • 4.1.1.2. Growing Application of Single-Use Systems (SUS)
    • 4.1.2. Restraints
      • 4.1.2.1. The Disadvantages or Limitations Associated With the Use of Biopharmaceutical Tubing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Silicone *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Plastic
  • 7.4. Metal

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmaceutical and Biopharmaceutical *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical
  • 8.4. Research and Development
  • 8.5. Diagnosis

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. W. L. Gore and Associates, Inc. *
    • 11.1.1. Company Overview
    • 11.1.2. Type Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. DuPont de Nemours, Inc.
  • 11.3. Freudenberg Group (Freudenberg Medical)
  • 11.4. REHAU Group (Raumedic AG)
  • 11.5. Genstar Capital LLC (TekniPlex)
  • 11.6. Holland Applied Technologies, Inc.
  • 11.7. Sartorius AG
  • 11.8. Saint-Gobain
  • 11.9. Ami Polymer
  • 11.10. Nordson Corporation

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us